These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23452678)

  • 1. Do stimulants prevent substance use and misuse among youth with attention-deficit/hyperactivity disorder? The answer is still maybe.
    Goldstein BI
    J Am Acad Child Adolesc Psychiatry; 2013 Mar; 52(3):225-7. PubMed ID: 23452678
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion.
    Faraone SV; Wilens TE
    J Clin Psychiatry; 2007; 68 Suppl 11():15-22. PubMed ID: 18307377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on attention deficit disorder.
    Harv Ment Health Lett; 2004 May; 20(11):4-7. PubMed ID: 15153391
    [No Abstract]   [Full Text] [Related]  

  • 4. Stimulant misuse in college for "pseudo-attention deficit disorder" during schizophrenia prodrome.
    Freudenreich O; Cather C; Holt D
    Am J Psychiatry; 2006 Nov; 163(11):2019. PubMed ID: 17074965
    [No Abstract]   [Full Text] [Related]  

  • 5. Attention deficit hyperactivity disorder and substance use disorders.
    Bukstein OG
    Curr Top Behav Neurosci; 2012; 9():145-72. PubMed ID: 21789746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of attention deficit/hyperactivity disorder and the use of stimulants in prison. Evaluation of the risks and benefits.
    Fructuoso A
    Rev Esp Sanid Penit; 2019; 21(2):113-114. PubMed ID: 31642863
    [No Abstract]   [Full Text] [Related]  

  • 7. Authors' reply.
    Groenman AP; Oosterlaan J; Rommelse NN; Franke B; Greven CU; Hoekstra PJ; Hartman CA; Luman M; Roeyers H; Oades RD; Sergeant JA; Buitelaar JK; Faraone SV
    Br J Psychiatry; 2014 Jun; 204(6):490-1. PubMed ID: 25029693
    [No Abstract]   [Full Text] [Related]  

  • 8. Stimulant treatment for ADHD.
    Verma R; Apala ; Kumari S; Dhiman V
    Br J Psychiatry; 2014 Jun; 204(6):490. PubMed ID: 25029692
    [No Abstract]   [Full Text] [Related]  

  • 9. A case report of Concerta misuse in a patient with comorbid substance use disorder and attention deficit hyperactivity disorder.
    Rizkallah E; Legault L; Pampoulova T; Lévesque S; Bélanger M; Stavro K; Chiasson JP; Potvin S
    Am J Addict; 2011; 20(5):478-9. PubMed ID: 21838849
    [No Abstract]   [Full Text] [Related]  

  • 10. Does stimulant treatment lead to substance use disorders?
    Faraone SV; Wilens T
    J Clin Psychiatry; 2003; 64 Suppl 11():9-13. PubMed ID: 14529324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the medicating ADHD increase or decrease the risk for later substance abuse?
    Wilens TE
    Braz J Psychiatry; 2003 Sep; 25(3):127-8. PubMed ID: 12975683
    [No Abstract]   [Full Text] [Related]  

  • 12. Update on Attention-Deficit/Hyperactivity Disorder.
    Soileau EJ
    Adolesc Med State Art Rev; 2014 Aug; 25(2):502-19. PubMed ID: 27132328
    [No Abstract]   [Full Text] [Related]  

  • 13. [The significance of attention-deficit hyperactivity disorder for the future of the child and the young].
    Penttilä J; Rintahaka P; Kaltiala-Heino R
    Duodecim; 2011; 127(14):1433-9. PubMed ID: 21888044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comment on Lambert and Hartsough (1998).
    Mick E; Biederman J; Faraone SV
    J Learn Disabil; 2000; 33(4):314; author reply 314-6. PubMed ID: 15493092
    [No Abstract]   [Full Text] [Related]  

  • 15. Substance use disorders in adolescents with attention-deficit/hyperactivity disorder.
    Bukstein O
    Adolesc Med State Art Rev; 2008 Aug; 19(2):242-53, viii. PubMed ID: 18822830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylphenidate: abuse and addiction.
    Prescrire Int; 2012 Oct; 21(131):241. PubMed ID: 23189380
    [No Abstract]   [Full Text] [Related]  

  • 17. Commentary on Kaye et al. (2013): Attention deficit disorder in substance use disorder-a hidden or a conspicuous comorbidity? What does it change for patients?
    Garcia FD
    Addiction; 2013 May; 108(5):932-3. PubMed ID: 23587082
    [No Abstract]   [Full Text] [Related]  

  • 18. Stimulant treatment for attention-deficit hyperactivity disorder and risk of developing substance use disorder.
    Groenman AP; Oosterlaan J; Rommelse NN; Franke B; Greven CU; Hoekstra PJ; Hartman CA; Luman M; Roeyers H; Oades RD; Sergeant JA; Buitelaar JK; Faraone SV
    Br J Psychiatry; 2013 Aug; 203(2):112-9. PubMed ID: 23846996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy for attention-deficit/hyperactivity disorder (ADHD) decreases the risk for substance abuse: findings from a longitudinal follow-up of youths with and without ADHD.
    Biederman J
    J Clin Psychiatry; 2003; 64 Suppl 11():3-8. PubMed ID: 14529323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What exactly are the benefits of stimulants for ADHD?
    Advokat C
    J Atten Disord; 2009 May; 12(6):495-8. PubMed ID: 19380518
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.